Search results for "Atenolol"

showing 10 items of 37 documents

Viscosity-mediated negative food effect on oral absorption of poorly-permeable drugs with an absorption window in the proximal intestine: In vitro ex…

2014

Concomitant food intake can diminish oral absorption of drugs with limited permeability and an absorption window in the proximal intestine, due to viscosity-mediated decrease in dosage form disintegration time and drug dissolution rate. Three poorly-permeable drugs (atenolol, metformin hydrochloride, and furosemide) exhibiting negative food effect, and one highly-soluble and highly-permeable (metoprolol tartrate), serving as a negative control, were selected for the study. In vitro and in silico tools were used to evaluate the influence of media viscosity on drug bioperformance under fasted and fed conditions. The obtained results demonstrated that increased medium viscosity in the presence…

Absorption (pharmacology)DrugMetoprolol Tartratemedia_common.quotation_subjectPharmaceutical ScienceAdministration OralPharmaceutical formulationPharmacologyDosage formPermeabilityFood-Drug InteractionsPharmacokineticsPoorly-permeable drugsFurosemideHumansDissolution testingSolubilityDisintegrationmedia_commonChromatographyChemistryViscosityReproducibility of ResultsHydrogen-Ion ConcentrationFood effectMetforminAtenololIntestinal AbsorptionSolubilityFoodDissolutionAbsorption simulationEuropean journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences
researchProduct

Micellar Liquid Chromatography:  A Worthy Technique for the Determination of β-Antagonists in Urine Samples

1998

Several beta-antagonists (acebutolol, atenolol, celiprolol, labetalol, metoprolol, nadolol, propranolol) were determined in urine samples with fluorometric detection after direct injection, in less than 15 min, with a micellar mobile phase of 0.1 M sodium dodecyl sulfate (SDS), 15% propanol, and 1% triethylamine at pH 3. The limits of detection (38 criterion) were usually between 3 and 30 ng/mL. The addition of propanol and triethylamine and the reduction of the pH of the mobile phase improved the efficiency of the chromatographic peaks that was rather low in pure micellar eluents. The selection of the composition of the mobile phase was easily performed through the use of an interpretive p…

Adrenergic beta-Antagonists1-PropanolHigh-performance liquid chromatographyAnalytical ChemistryPropanolSurface-Active Agentschemistry.chemical_compoundEthylaminesmedicineHumansSodium dodecyl sulfateTriethylamineMicellesDetection limitChromatographySodium Dodecyl SulfateHydrogen-Ion ConcentrationAtenololPropranololAcebutololSpectrometry FluorescenceAtenololchemistryMicellar liquid chromatographyChromatography LiquidMetoprololmedicine.drugAnalytical Chemistry
researchProduct

Treatment of hypertension with a combination of nifedipine and atenolol compared with atenolol alone. Preliminary report.

1988

AdultMaleAdolescentNifedipinebusiness.industryPharmacology toxicologyBlood PressurePharmacologyMiddle AgedAtenololPharmacotherapyNifedipineAtenololPreliminary reportHypertensionmedicineHumansPharmacology (medical)Drug Therapy CombinationFemalebusinessmedicine.drugAgedDrugs
researchProduct

Atenolol interaction with aspirin, allopurinol, and ampicillin.

1983

Atenolol kinetics were investigated in six healthy subjects after 100 mg orally, as monotherapy a 6-day treatment began 48 hr later. After a therapy-free interval of 4 wk, the same subjects received the same dose of atenolol with 1 gm ampicillin, 500 mg aspirin, and with 300 mg allopurinol. Allopurinol and aspirin did not substantially alter the kinetics of atenolol. After a single oral dose of 100 mg atenolol combined with 1 gm ampicillin, the bioavailability of atenolol was reduced to 36 +/- 5% compared to 60 +/- 8% after monotherapy. During long-term treatment with atenolol and ampicillin the bioavailability of atenolol fell to 24% (P less than 0.01). Mean peak plasma levels were lowered…

AdultMaleCombination therapyUrinary systemAllopurinolPhysical ExertionAllopurinolBiological AvailabilityBlood PressurePharmacologyPropanolaminesHeart RateAmpicillinmedicineHumansPharmacology (medical)Drug Interactionscardiovascular diseasesPharmacologyAspirinAspirinChemistryAtenololBioavailabilityKineticsBlood pressureAtenololAmpicillinFemalecirculatory and respiratory physiologymedicine.drugClinical pharmacology and therapeutics
researchProduct

Interaction of atenolol with furosemide and calcium and aluminum salts

1981

Six healthy subjects were treated with 100 mg atenolol. After a therapy-free interval of 4 wk the same subjects received the same dose of atenolol with furosemide, 40 mg, with calcium (as the lactate gluconate and carbonate), 500 mg, or with aluminum hydroxide, 5.6 gm. Atenolol alone and in combination was administered first as a single oral dose; a long-term 6-day treatment began 48 hr later. Addition of furosemide did not influence atenolol kinetics, but aluminum hydroxide led to an insignificant reduction (P greater than 0.05) of mean peak plasma levels of about 20% and of the area under the plasma concentration-time curve (AUC -infinity) from 5818 to 4353 ng ml-1 hr (P greater than 0.05…

AdultMaleTachycardiamedicine.medical_specialtyPhysical Exertionchemistry.chemical_elementBlood PressureCalciumPharmacologyPropanolaminesFurosemideHeart RateInternal medicinemedicineHumansDrug InteractionsPharmacology (medical)PharmacologyHealthy subjectsFurosemideAluminum saltsMiddle AgedAtenololKineticsPeak plasmaEndocrinologyBlood pressureAtenololchemistryHypertensionCalciumFemalemedicine.symptomAluminumcirculatory and respiratory physiologymedicine.drugClinical Pharmacology and Therapeutics
researchProduct

Factors related to the impact of antihypertensive treatment in antioxidant activities and oxidative stress by-products in human hypertension

2004

The objective was to study factors related to the changes induced by antihypertensive treatment on oxidative status, antioxidant activities, and reactive oxygen species by-products in whole blood and mononuclear peripheral cells. Eighty-nine hypertensive patients (mean age 46 years, 46 men, average 24-h blood pressure 139/88 mm Hg, body mass index 29) were included. After 3 months of nonrandomized allocation to antihypertensive treatment (20 nonpharmacologic, 36 beta-blockers, 33 angiotensin receptor blocker), oxidized/reduced glutathione ratio and malondialdehyde were significantly reduced, and the activity of superoxide dismutase, catalase, and glutathione peroxidase was significantly inc…

AdultMalemedicine.medical_specialtyAntioxidantmedicine.medical_treatmentAngiotensin-Converting Enzyme Inhibitorsmedicine.disease_causeBenzoatesAntioxidantsSuperoxide dismutasechemistry.chemical_compoundInternal medicineInternal MedicinemedicineHumansTelmisartanAntihypertensive AgentsWhole bloodchemistry.chemical_classificationReactive oxygen speciesbiologybusiness.industryGlutathione peroxidaseGlutathioneMiddle AgedMalondialdehydeOxidative StressHydrochlorothiazideTreatment OutcomeEndocrinologyAtenololchemistryHypertensionbiology.proteinBenzimidazolesDrug Therapy CombinationFemalebusinessOxidative stressDNA DamageAmerican Journal of Hypertension
researchProduct

Effects of nebivolol and atenolol on central aortic pressure in hypertensive patients: a multicenter, randomized, double-blind study.

2013

The main objective was to compare the mean change in augmentation index of hypertensive patients treated with nebivolol or atenolol.Multicenter, double-blind randomized study conducted in six Spanish centers. We enrolled outpatients between the ages of 40 and 65 years with mild or moderate essential hypertension (systolic blood pressure, SBP ≥ 140 mmHg to ≤ 179 mmHg and diastolic blood pressure, DBP ≥ 90 mmHg to ≤ 109 mmHg after a 2-week run-in placebo period). Patients received nebivolol 5 mg or atenolol 50 mg once daily. At week 3, atenolol could be titrated up to 100 mg qd for non-responders. Additionally, patients not achieving normal blood pressure after 6 weeks could be treated with 2…

AdultMalemedicine.medical_specialtyBlood PressureEssential hypertensionlaw.inventionNebivololHydrochlorothiazideRandomized controlled trialDouble-Blind MethodlawInternal medicineInternal MedicinemedicineHumansBenzopyransAntihypertensive AgentsAgedbusiness.industryGeneral MedicineMiddle AgedAtenololmedicine.diseaseNebivololPulse pressureBlood pressureAtenololEthanolaminesAnesthesiaHypertensionCardiologyAortic pressureFemaleEssential HypertensionCardiology and Cardiovascular Medicinebusinessmedicine.drugBlood pressure
researchProduct

Effects of drug therapy on cardiac arrhythmias and ischemia in hypertensives with LVH.

2001

Left ventricular hypertrophy (LVH) in hypertensive subjects is associated with an increased prevalence of ventricular arrhythmias. To evaluate the effect of antihypertensive treatment on cardiac arrhythmias (CA) and transient episodes of myocardial ischemia (TEMI), we studied 46 hypertensive patients with LVH, divided into four groups randomly treated with enalapril, hydrochlorothiazide (HCTZ), atenolol, or verapamil (SR-V) for 6 months. Office blood pressure and office heart rate values were recorded, in basal conditions, after 1 and 6 months of treatment, and all patients underwent echocardiography, electrocardiographic Holter monitoring, and stress testing. All drugs significantly lowere…

AdultMalemedicine.medical_specialtyHeart diseaseMyocardial IschemiaBlood PressureLeft ventricular hypertrophyHydrochlorothiazideEnalaprilInternal medicineHeart rateInternal MedicinemedicineHumanscardiovascular diseasesEnalaprilAntihypertensive AgentsAgedmedicine.diagnostic_testbusiness.industryArrhythmias CardiacMiddle Agedmedicine.diseaseAtenololBlood pressureHydrochlorothiazideTreatment OutcomeAtenololVerapamilHypertensioncardiovascular systemCardiologyElectrocardiography AmbulatoryFemaleHypertrophy Left VentricularbusinessElectrocardiographyAnti-Arrhythmia Agentsmedicine.drugAmerican journal of hypertension
researchProduct

Factors Related to the Occurrence of Microalbuminuria During Antihypertensive Treatment in Essential Hypertension

2002

The objective of the study was to assess the factors related to the occurrence of microalbuminuria during the follow-up of a young adult group with essential hypertension that had not been previously treated. Normo-albuminuric essential hypertensives, <50 years old, who had not been previously treated with antihypertensive drugs and who did not have diabetes mellitus were included. After the initial evaluation, patients were treated using only nonpharmacological measures (n=62), β-blockers (n=38), ACE inhibitors (n=64), calcium channel blockers (n=8), and several classes (n=15). Measurements were taken for office blood pressure, biochemical profile, and 24-hour urinary albumin excretion…

AdultMalemedicine.medical_specialtyNifedipineAdrenergic beta-AntagonistsAngiotensin-Converting Enzyme InhibitorsEssential hypertensionEnalaprilLisinoprilRisk FactorsInternal medicineInternal MedicinemedicineAlbuminuriaBisoprololHumansYoung adultAntihypertensive AgentsProportional Hazards ModelsProteinuriabusiness.industryFollow up studiesMiddle AgedCalcium Channel Blockersmedicine.diseaseTreatment OutcomeEndocrinologyBlood pressureAtenololHypertensionAlbuminuriaRegression AnalysisFemaleMicroalbuminuriamedicine.symptombusinessPreviously treatedHypertension
researchProduct

Pharmacokinetics of atenolol in relation to renal function

1981

The plasma levels and urinary excretion of carteolol and its main metabolites 8-hydroxycarteolol and carteolol glucuronide were investigated in 6 healthy subjects and 9 patients with varying degrees of renal impairment following a single oral dose of 30 mg carteolol hydrochloride. In healthy subjects the half-life of carteolol was 7.1 h. 63% of the administered dose was recovered unchanged in urine, and in all 84% was excreted by the kidneys. The renal clearance of carteolol was 255 ml/min. In chronic renal failure (CRF) the terminal half-life was increased to a maximum of 41 h. Both the elimination rate constant and renal clearance were closely related to the creatinine clearance. In CRF t…

AdultMalemedicine.medical_specialtyUrologyAdministration OralRenal functionCarteolol HydrochloridePropanolamineschemistry.chemical_compoundPharmacokineticsElimination rate constantRenal DialysisInternal medicinemedicineHumansPharmacology (medical)CarteololAgedPharmacologyKidneyCreatinineMaintenance dosebusiness.industryGeneral MedicineMiddle AgedKineticsEndocrinologymedicine.anatomical_structureAtenololchemistryInjections IntravenousFemaleKidney DiseasesbusinessGlomerular Filtration Ratemedicine.drugEuropean Journal of Clinical Pharmacology
researchProduct